spinifex-pharmaceuticals

Médias

Spinifex Pharmaceuticals Raises US$45m in Series C Financing

Médias

Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia

Médias

Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch

Médias

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy

Médias

Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia